Current resesarch projects include:

The largest study at present is the Preventing Atopic Dermatitis and ALLergies in children (PreventADALL) study, a multicenter, Scandinavian mother-child factorially designed randomised clinical trial and observational study targeting primary prevention of allergies as well as identifying early life factors that may be implicated in the development of non-communciable diseases. The study included approximately 2700 pregnant women in mid-pregnancy from December 2014, as well as around 2400 of their offspring. Follow-up studies are ongoing through early childhood, and will continue into adult age at Oslo University Hospital, Hospital trust Østfold, and at Karolinska Institute/University hospital, Stockholm, Sweden.
Primary prevention was shown to be effective for reducing allergy to any of peanut, milk, egg or wheat at 3 years of age by introducing tastes of these foods between 3 and 4 months of age complementary to breast or formulae feeding and continuing at least 4 times weekly, gradually including these in the child's regular diet. On the other hand, we were unable to show benefit from frequent oil-baths/facial cream from 2 weeks of age, with no decrease in atopic dermatitis development at 1 or 3 years of age.
The PreventADALL study has a broad network of collaborators, spanning topics of early diet, environment, microbiome, infections, life-style and other early potential determinants for development of allergic diseases, cardiovascular disese and other NCDs.

Randomised clinical trials such as the NAPiC (Norwegian Antibiotics for Pnumonia in Children) study currently recruiting young children from hospitals in Norway (PI Håvard O Skjerven), the Take-away Peanut allergy trial of oral immunotherapy in children with severe peanut allergy (PI Geir Håland) and testing efficiency and safety of Mechanical Cough support in children with neurodisability (PI Vegard Hovland).

Epidemiological and studies include Primary Cliary Dyskinesia prevalence and early diagnostics (PI Suzanne Crowley) and the Environment and Childhood asthma study from 1992 (PI Karin C. Lødrup Carlsen), data being anonymized by the end of 2023, as well as contributing in the European SPACE register (Severe asthma in Children in Europe) aiming at fascilitating access to early randomised trials for novel treatment of severe asthma in chidlren.